.png)
Introduction
In 2023, the demand for a new class of weight-loss treatments skyrocketed. Initially approved for managing type 2 diabetes, glucagon-like peptide-1 receptor agonist drugs (GLP-1s) such as Wegovy, Zepbound, Ozempic, and Mounjaro have become popular for weight loss despite their high costs and limited insurance coverage. Wegovy, Saxenda, and Zepbound are FDA-approved for chronic weight management in adults, while others like Ozempic are frequently prescribed off-label for weight loss.
As a result of this massive demand, the FDA has placed Ozempic and Wegovy on its shortages list. This isn't just a bureaucratic update: it's a golden opportunity for compounding pharmacies. With the demand for semaglutide soaring and the supply of the brand name drug limited, pharmacies that can compound and distribute semaglutide-based medications are in an enviable position. This moment is being dubbed the "Gold Rush" of Ozempic, and those who navigate it wisely can expect substantial profits.
Some estimates project GLP-1 sales will exceed $100 billion by 2030. As a pharmacy owner, it's crucial to stay updated on the evolving regulatory landscape and reimbursement policies for these medications. Having a skilled attorney on hand is essential to navigate potential legal challenges. Here are key considerations to keep in mind.
State Prescribing Standards for Obesity Medication
We have written about the Increasing Regulatory Threats Compounding Pharmacies Face
Different states have specific requirements for prescribing weight-loss medications. Understanding these standards is crucial for ensuring compliance and avoiding legal repercussions.
The list of states where Boards of Pharmacy have imposed regulations on weight loss drug prescriptions and distribution is growing, and currently includes North Carolina, West Virginia, Mississippi, California, Florida, New Jersey, and Virginia.
It is always recommended to consult with a healthcare attorney who is aware of the ever-changing regulatory landscape to ensure your pharmacy's practices align with state laws to avoid penalties and maintain your professional license.
Telehealth Prescriber Requirements Also Vary By State
Telehealth standards also vary by state, including who can prescribe via telehealth and the technologies allowed for patient examinations and establishing patient-physician relationships.
A physician’s license was suspended in May 2023 by the Mississippi State Board of Medical Licensure for prescribing Ozempic through an instant-messaging platform. Several violations included failure to establish a valid physician-patient relationship, underscoring the importance of understanding the nuances of state-specific telehealth regulations.
As the trend of weight-loss-related prescribing grows, expect increased enforcement of these laws. Ensure your telehealth services comply with state regulations to avoid disciplinary actions. Your attorney can provide guidance on navigating these complex requirements.
Limitations on Off-Label Prescribing of GLP-1s
A recent analysis found that more than half of new Ozempic and Mounjaro users did not have type 2 diabetes. Demand for GLP-1 drugs has surged, and some are in short supply. Some companies are prioritizing access for Type 2 diabetes patients over off-label weight-loss uses. Many patients are turning to online and out-of-country pharmacies to obtain the medications.
In June 2023, Anthem Blue Cross Blue Shield warned prescribers about off-label Ozempic prescriptions for non-diabetic patients, citing insufficient evidence of diabetes in 60% of cases. Off-label use that doesn't meet criteria exposes prescribers to potential insurance fraud claims and disciplinary actions.
In August 2023, the Mississippi Board of Medical Licensure prohibited unapproved use of GLP-1 medications specifically for weight loss based on FDA and state pharmacy board information.
If a prescription is falsely claimed as on-label when it is not, such a misrepresentation can expose the prescriber to potential insurance fraud accusations, which may result in civil and/or criminal penalties. Additionally, state professional boards may discipline prescribers for prescribing inappropriate medications or incorrect quantities.
FDA and State Restrictions on Compounding GLP-1s
Increased GLP-1 prescribing and compounding have attracted attention from state boards and the FDA. The Alabama Board of Medical Examiners voiced their “Concerns with Semaglutide and Other GLP-1 Receptor Agonists” and issued guidance against improper GLP-1 compounding, prohibiting the use of non-pharmaceutical grade ingredients or those not from FDA-registered establishments.
In 2023, the FDA clarified that compounded drugs could be made with fewer restrictions when listed on the FDA’s drug shortage list but warned against using salt forms of semaglutide that do not meet federal requirements.
Conclusion
The rise of GLP-1s for chronic weight management significantly impacts US obesity care. As these drugs become more accessible, federal and state regulators and payors are increasingly scrutinizing their use. As a pharmacy owner, staying informed about regulatory changes and ensuring your practices comply with federal, state, and payor requirements is crucial. Having a skilled attorney on hand will help you navigate the evolving landscape effectively, mitigate risks, and maintain the trust and safety of your customers.
Please contact us if you have any specific questions regarding your pharmacy or semaglutide program.
Frequently Asked Questions
How to navigate the new frontier of Ozempic shortage?
To navigate the new frontier of the Ozempic shortage effectively, consider seeking advice from a knowledgeable attorney. They can help you understand and comply with regulatory requirements, ensure legal compliance in compounding and distributing semaglutide, and provide guidance on managing the legal risks associated with the shortage.
What are some of the semaglutide distribution caveats I should be aware of?
When distributing semaglutide, here are some important caveats to be aware of:
- Regulatory Compliance: Ensure compliance with all FDA and state regulations regarding the compounding and distribution of semaglutide. This includes using only approved forms of the drug and following proper compounding procedures.
- Documentation and Record-Keeping: Keep detailed records of all compounding and distribution activities. This includes documenting sources of ingredients, compounding processes, and distribution channels to ensure traceability and accountability.
- Legal Liability: Be aware of the potential legal liabilities associated with compounding and distributing semaglutide. This includes the risk of lawsuits related to product quality, adverse reactions, or regulatory non-compliance.
- Market Dynamics: Stay informed about market trends and supply chain issues. The demand for semaglutide may fluctuate, so being aware of these dynamics can help you plan your production and distribution strategies effectively.
- Ethical Considerations: Ensure ethical practices in the marketing and distribution of semaglutide. Avoid making unsupported claims about the drug's effectiveness and be transparent with patients and healthcare providers about its compounded nature.
By being aware of and addressing these caveats, you can help ensure the successful and compliant distribution of semaglutide.
How can I ensure compliance with a constantly changing landscape?
Ensuring compliance with a constantly changing regulatory landscape involves several key strategies:
- Stay Informed: Regularly monitor updates from regulatory bodies such as the FDA and state pharmacy boards. Subscribe to newsletters, attend webinars, and participate in industry conferences to stay current on changes.
- Training and Education: Continuously train and educate your staff on the latest regulations and compliance requirements. Ensure they understand the importance of adhering to these standards in their daily tasks.
- Hire a Compliance Officer: Appoint a dedicated compliance officer or team responsible for monitoring regulatory changes and implementing necessary adjustments within your organization.
- Develop Standard Operating Procedures (SOPs): Create detailed SOPs that outline compliance processes and ensure they are updated regularly to reflect the latest regulations. Make sure all employees follow these procedures consistently.
- Use Compliance Software: Implement compliance management software to track regulatory changes, manage documentation, and automate compliance tasks. This can help streamline the process and reduce the risk of human error.
- Conduct Regular Audits: Perform regular internal audits to ensure all aspects of your operations comply with current regulations. Identify any areas of non-compliance and take corrective actions promptly.
- Engage Legal Counsel: Consult with legal experts who specialize in pharmaceutical regulations. They can provide guidance on complex regulatory issues and help you navigate any changes effectively.
- Join Professional Organizations: Become a member of professional organizations related to your field. These organizations often provide valuable resources, updates, and networking opportunities that can help you stay informed and compliant.
- Communicate with Regulators: Maintain open lines of communication with regulatory authorities. Seek clarification when needed and ensure you understand the implications of any regulatory changes.
- Risk Management: Implement a robust risk management strategy to identify potential compliance risks and develop plans to mitigate them. This proactive approach can help you adapt to changes more effectively.
By following these strategies, you can ensure your organization remains compliant even as regulations evolve.
HLA Convinces Optum to Reverse PBM Audit Termination
Health Law Alliance is pleased to announce that Optum recently agreed to reverse its network termination of a Texas pharmacy client despite significant claim discrepancies based on inventory shortages, patient denials, and other alleged violations of the terms and conditions of the Provider Manual and network enrollment agreements.
Read More >>HLA's Lawsuit Against Optum Achieves Return of Hundreds of Thousands of Dollars in Withheld Reimbursement
Health Law Alliance's lawsuit against Optum has resulted in the immediate release of hundreds of thousands of dollars in reimbursement that Optum unlawfully refused to release to our client prior to being sued.
Read More >>HLA Attorney Anthony Mahajan Wins Dismissal of False Claims Lawsuit Against Oncology Dispensing Practice
Health Law Alliance's Anthony Mahajan is pleased to announce the complete dismissal of a lawsuit brought on behalf of the federal government against a cancer care provider for the submission of false Medicare claims for oncology drugs.
Read More >>HLA Files Emergency Texas Lawsuit Against Optum PBM Audit Termination
Health Law Alliance announces the filing of an emergency lawsuit in federal court for the Northern District of Texas, Dallas Division, to stop Optum's termination of an independent pharmacy that dispensed medications on telemedicine prescriptions and force Optum to comply with federal and state "prompt payment" laws that prohibit withholding of reimbursement.
Read More >>.png)